 The study found that patients with severe asthma are more likely to have co-expressed multiple T2 biomarkers, such as blood and sputum eosinophilia, than those with mild to moderate asthma. This suggests that treatments for severe asthma should target multiple T2 pathways rather than focusing solely on one or two. Furthermore, implementation of airway inflammatory in clinical practice is important as it can identify which patients have the most treatable traits, regardless of their disease severity.